It is recommended that those vaccinated with the first dose of Astra Zeneca continue with a second dose of the same vaccine, unless they have complications with the first dose.
This was stated to BNR by Prof. Mariana Murdzheva, Rector of the Medical University in Plovdiv and a member of the National Vaccination Headquarters.
She pointed out that thrombosis as a clinical manifestation is well known – headache, shortness of breath, chest pain, swelling in the legs, confusion, blurred vision and bleeding.
At the moment, the EMA does not report any cases of thrombosis after the second dose of Astra Zeneca, said Prof. Murdzheva.
She explained that it was recommended that the second dose of Astra Zeneca be given between the 4th and 11th week after the first dose. In practice, in our country the first vaccinations with the second dose of AstraZeneca should be made after April 16. People who received the first dose of Astra Zeneca should wait until the end of the month, Prof. Murdzheva recommended.
There is no consensus in the European Union on the age of women who are not recommended to be vaccinated with the vector vaccine.
About two-thirds of reported cases of thrombosis after Astra Zeneca vaccination are in women under the age of 60, with more than 34 million vaccinated in the EU and the UK.
In the United Kingdom, the use of Astra Zeneca is not recommended for women under 30 years of age.
This is because they most often use contraceptives, which in themselves increase the thrombotic risk. In our country, the Vaccination Headquarters recommends that the Astra Zeneca vaccine not be given to women under the age of 60. This is also the case in Germany, Spain and Italy, said Prof. Murdzheva.
The risk of thrombosis is many times lower than the risk of infection. The benefit-risk balance is positive. It is in favor of the Astra Zeneca vaccine, said Prof. Mariana Murdzheva.
This is not the only vector vaccine that carries a risk of thrombosis when administered. Such is the case with the Ebola vaccine, for example, and the medical community knows this, said the clinical immunologist.
For RNA vaccines, there are currently no reports of thrombotic complications.
– .
